Sp100 provides intrinsic immunity against human papillomavirus infection

mBio

Volumn 4, Issue 6, 2013, Pages

  Stepp, Wesley H ^a,b   Meyers, Jordan M ^a,c   McBride, Alison A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAXX PROTEIN; NUCLEAR PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN SP100; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DNA REPLICATION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNITY; KERATINOCYTE; NONHUMAN; NUCLEAR DOMAIN 10 BODY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; VIRUS TRANSCRIPTION;

ANTIGENS, NUCLEAR; AUTOANTIGENS; CELLS, CULTURED; GENE KNOCKDOWN TECHNIQUES; HUMAN PAPILLOMAVIRUS 18; HUMANS; KERATINOCYTES;

EID: 84891602166     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00845-13     Document Type: Article

References (52)

1. zur Hausen H. 1996. Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta 1288:F55-F78.
2. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
3. Malmgaard L. 2004. Induction and regulation of IFNs during viral infections. J. Interferon Cytokine Res. 24:439-454.
4. Weidtkamp-Peters S, Lenser T, Negorev D, Gerstner N, Hofmann TG, Schwanitz G, Hoischen C, Maul G, Dittrich P, Hemmerich P. 2008. Dynamics of component exchange at PML nuclear bodies. J. Cell Sci. 121:2731-2743.
5. Guldner HH, Szostecki C, Grötzinger T, Will H. 1992. IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J. Immunol. 149:4067-4073.
6. Spector DL. 2001. Nuclear domains. J. Cell Sci. 114:2891-2893.
7. Sternsdorf T, Jensen K, Reich B, Will H. 1999. The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J. Biol. Chem. 274:12555-12566.
8. Nefkens I, Negorev DG, Ishov AM, Michaelson JS, Yeh ET, Tanguay RM, Müller WE, Maul GG. 2003. Heat shock and CD2 exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently. J. Cell Sci. 116:513-524.
9. Bernardi R, Pandolfi PP. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8:1006-1016.
10. Everett RD, Freemont P, Saitoh H, Dasso M, Orr A, Kathoria M, Parkinson J. 1998. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110and proteasome-dependent loss of several PML isoforms. J. Virol. 72:6581-6591.
11. Kim YE, Lee JH, Kim ET, Shin HJ, Gu SY, Seol HS, Ling PD, Lee CH, Ahn JH. 2011. Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression. J. Virol. 85: 11928-11937.
12. Tavalai N, Adler M, Scherer M, Riedl Y, Stamminger T. 2011. Evidence for a dual antiviral role of the major nuclear domain 10 component Sp100 during the immediate-early and late phases of the human cytomegalovirus replication cycle. J. Virol. 85:9447-9458.
13. Maul GG, Negorev D. 2008. Differences between mouse and human cytomegalovirus interactions with their respective hosts at immediate early times of the replication cycle. Med. Microbiol. Immunol. 197: 241-249.
14. Cantrell SR, Bresnahan WA. 2006. Human cytomegalovirus (HCMV) UL82 gene product (pp71) relieves hDaxx-mediated repression of HCMV replication. J. Virol. 80:6188-6191.
15. Tavalai N, Papior P, Rechter S, Stamminger T. 2008. Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection. J. Virol. 82:126-137.
16. Glass M, Everett RD. 2013. Components of promyelocytic leukemia nuclear bodies (ND10) act cooperatively to repress herpesvirus infection. J. Virol. 87:2174-2185.
17. Kyratsous CA, Silverstein SJ. 2009. Components of nuclear domain 10 bodies regulate varicella-zoster virus replication. J. Virol. 83:4262-4274.
18. Tavalai N, Papior P, Rechter S, Leis M, Stamminger T. 2006. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J. Virol. 80:8006-8018.
19. Schreiner S, Wimmer P, Sirma H, Everett RD, Blanchette P, Groitl P, Dobner T. 2010. Proteasome-dependent degradation of Daxx by the viral E1B-55K protein in human adenovirus-infected cells. J. Virol. 84: 7029-7038.
20. Day PM, Baker CC, Lowy DR, Schiller JT. 2004. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc. Natl. Acad. Sci. U. S. A. 101:14252-14257.
21. Day PM, Roden RB, Lowy DR, Schiller JT. 1998. The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J. Virol. 72:142-150.
22. Nakahara T, Lambert PF. 2007. Induction of promyelocytic leukemia (PML) oncogenic domains (PODs) by papillomavirus. Virology 366: 316-329.
23. Florin L, Schäfer F, Sotlar K, Streeck RE, Sapp M. 2002. Reorganization of nuclear domain 10 induced by papillomavirus capsid protein L2. Virology 295:97-107.
24. Karanam B, Peng S, Li T, Buck C, Day PM, Roden RB. 2010. Papillomavirus infection requires gamma secretase. J. Virol. 84:10661-10670.
25. Florin L, Sapp C, Streeck RE, Sapp M. 2002. Assembly and translocation of papillomavirus capsid proteins. J. Virol. 76:10009-10014.
26. Becker KA, Florin L, Sapp C, Sapp M. 2003. Dissection of human papillomavirus type 33 L2 domains involved in nuclear domains (ND) 10 homing and reorganization. Virology 314:161-167.
27. Becker KA, Florin L, Sapp C, Maul GG, Sapp M. 2004. Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles. J. Virol. 78: 1121-1128.
28. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss JF III, Maul GG. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:221-234.
29. Lace MJ, Anson JR, Klingelhutz AJ, Lee JH, Bossler AD, Haugen TH, Turek LP. 2009. Human papillomavirus (HPV) type 18 induces extended growth in primary human cervical, tonsillar, or foreskin keratinocytes more effectively than other high-risk mucosal HPVs. J. Virol. 83: 11784-11794.
30. Negorev DG, Vladimirova OV, Ivanov A, Rauscher F III, Maul GG. 2006. Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression. J. Virol. 80:8019-8029.
31. Lacks SA. 1980. Purification and properties of the complementary endonucleases DpnI and DpnII. Methods Enzymol. 65:138-146.
32. Reynolds A, Anderson EM, Vermeulen A, Fedorov Y, Robinson K, Leake D, Karpilow J, Marshall WS, Khvorova A. 2006. Induction of the interferon response by siRNA is cell type-and duplex lengthdependent. RNA 12:988-993.
33. Distler JH, Jüngel A, Kurowska-Stolarska M, Michel BA, Gay RE, Gay S, Distler O. 2005. Nucleofection: a new, highly efficient transfection method for primary human keratinocytes. Exp. Dermatol. 14:315-320.
34. Boutell C, Everett RD. 2013. Regulation of alphaherpesvirus infections by the ICP0 family of proteins. J. Gen. Virol. 94:465-481.
35. Walters MS, Kyratsous CA, Silverstein SJ. 2010. The RING finger domain of varicella-zoster virus ORF61p has E3 ubiquitin ligase activity that is essential for efficient autoubiquitination and dispersion of Sp100containing nuclear bodies. J. Virol. 84:6861-6865.
36. Seeler JS, Marchio A, Sitterlin D, Transy C, Dejean A. 1998. Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemiaassociated nuclear bodies and the chromatin compartment. Proc. Natl. Acad. Sci. U. S. A. 95:7316-7321.
37. Newhart A, Negorev DG, Rafalska-Metcalf IU, Yang T, Maul GG, Janicki SM. 2013. Sp100A promotes chromatin decondensation at a cytomegalovirus-promoter-regulated transcription site. Mol. Biol. Cell 24:1454-1468.
38. Negorev DG, Vladimirova OV, Maul GG. 2009. Differential functions of interferon-upregulated Sp100 isoforms: herpes simplex virus type 1 promoter-based immediate-early gene suppression and PML protection from ICP0-mediated degradation. J. Virol. 83:5168-5180.
39. Howley PM, Schenborn ET, Lund E, Byrne JC, Dahlberg JE. 1985. The bovine papillomavirus distal enhancer is not cis essential for transformation or for plasmid maintenance. Mol. Cell. Biol. 5:3310-3315.
40. McBride AA, Howley PM. 1991. Bovine papillomavirus with a mutation in the E2 serine 301 phosphorylation site replicates at a high copy number. J. Virol. 65:6528-6534.
41. Jiang M, Entezami P, Gamez M, Stamminger T, Imperiale MJ. 2011. Functional reorganization of promyelocytic leukemia nuclear bodies during BK virus infection. mBio 2(1):e00281-11. doi:10.1128/mBio.00281-11.
42. Ishov AM, Maul GG. 1996. The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition. J. Cell Biol. 134:815-826.
43. Swindle CS, Zou N, Van Tine BA, Shaw GM, Engler JA, Chow LT. 1999. Human papillomavirus DNA replication compartments in a transient DNA replication system. J. Virol. 73:1001-1009.
44. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. 2009. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 5:e1000318. doi:10.1371/journal.ppat.1000318.
45. Everett RD, Lomonte P, Sternsdorf T, van Driel R, Orr A. 1999. Cell cycle regulation of PML modification and ND10 composition. J. Cell Sci. 112:4581-4588.
46. 1. J. Cell Sci. 119:1034-1042.
47. Cole ST, Danos O. 1987. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses repeated structure E6 and E7 gene products. J. Mol. Biol. 193: 599-608.
48. Romanczuk H, Howley PM. 1992. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc. Natl. Acad. Sci. U. S. A. 89:3159-3163.
49. Chapman S, Liu X, Meyers C, Schlegel R, McBride AA. 2010. Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor. J. Clin. Invest. 120:2619-2626.
50. Sakakibara N, Chen D, Jang MK, Kang DW, Luecke HF, Wu S-Y, Chiang C-M, McBride AA. Brd4 is displaced from HPV replication factories as they expand and amplify viral DNA. PLoS Pathog. doi:10.1371/journal.ppat.1003777.
51. Pyeon D, Lambert PF, Ahlquist P. 2005. Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc. Natl. Acad. Sci. U. S. A. 102:9311-9316.
52. Van Doorslaer K, Tan Q, Xirasagar S, Bandaru S, Gopalan V, Mohamoud Y, Huyen Y, McBride AA. 2013. The papillomavirus Episteme: a central resource for papillomavirus sequence data and analysis. Nucleic Acids Res. 41:D571-D578.